Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)
NCT ID: NCT01109121
Last Updated: 2011-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
112 participants
INTERVENTIONAL
2010-06-30
2011-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia
NCT01052987
Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia
NCT00995618
Combining Lesinurad With Allopurinol in Inadequate Responders
NCT01493531
Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout
NCT05253833
Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat
NCT01510769
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Allopurinol
Allopurinol
Allopurinol
Allopurinol 400 mg, QD
Combination 400
Tranilast and Allopurinol
Combination 400
Tranilast 300 mg QD; Allopurinol 400 mg QD
Combination 600
Tranilast and Allopurinol
Combination 600
Tranilast, 300 mg QD; Allopurinol 600 mg QD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Combination 400
Tranilast 300 mg QD; Allopurinol 400 mg QD
Allopurinol
Allopurinol 400 mg, QD
Combination 600
Tranilast, 300 mg QD; Allopurinol 600 mg QD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Severe gout, demonstrated by 3 or more gout flares in the previous 12 months, or the presence of at least one gout tophus or gouty arthritis
* Hyperuricemia with a sUA ≥8.0 mg/dL
Exclusion Criteria
* Known hypersensitivity to any of the components of tranilast or allopurinol
* Known history of xanthinuria or kidney stones
* Use of an investigational drug within 30 days
* Presence of, or history of, cancer with the exception of completely excised, non-metastatic squamous cell and basal cell carcinomas of the skin
* Subject is planning or likely to require a surgical procedure during the study
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nuon Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nuon Therapeutics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Director, Nuon Clinical Trials Group
Role: STUDY_DIRECTOR
Nuon Therapeutics, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nuon Investigative Site
La Jolla, California, United States
Nuon Investigative Site
Santa Maria, California, United States
Nuon Investigative Site
Washington D.C., District of Columbia, United States
Nuon Investigative Site
New Port Richey, Florida, United States
Nuon Investigative Site
Honolulu, Hawaii, United States
Nuon Investigative Site
Boise, Idaho, United States
Nuon Investigative Site
Bloomington, Indiana, United States
Nuon Investigative Site
Owensboro, Kentucky, United States
Nuon Investigative Site
Baltimore, Maryland, United States
Nuon Investigative Site
Wheaton, Maryland, United States
Nuon Investigative Site
Billings, Montana, United States
Nuon Investigative Site
Omaha, Nebraska, United States
Nuon Investigative Site
Reno, Nevada, United States
Nuon Investigative Site
Teaneck, New Jersey, United States
Nuon Investigative Site
Durham, North Carolina, United States
Nuon Investigative Site
Cincinnati, Ohio, United States
Nuon Investigative Site
Oklahoma City, Oklahoma, United States
Nuon Investigative Site
Lake Oswego, Oregon, United States
Nuon Investigative Site
Duncansville, Pennsylvania, United States
Nuon Investigative Site
West Reading, Pennsylvania, United States
Nuon Investigative Site
Charleston, South Carolina, United States
Nuon Investigative Site
Greenville, South Carolina, United States
Nuon Investigative Site
Waco, Texas, United States
Nuon Investigative Site
Spokane, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A3007GT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.